OPERATING REVIEW CONTINUED NNZ-2591 (ERCANETIDE) FOR MULTIPLE NEUROLOGICAL CONDITIONS * Rett and Fragile X syndromes are licensed to Acadia, with same economics to Neuren as trofinetide; Neuren retains worldwide rights to all other indications TO FIND OUT MORE: www.pmsf.org www.pitthopkins.org www.cureshank.org www.hopeforhie.org Neuren is developing NNZ-2591 for multiple serious neurological conditions. The estimated number of potential patients being targeted across these conditions is multiple times larger than Rett syndrome. In designing and executing the NNZ-2591 development program, Neuren has been able to leverage the extensive and highly relevant experience the Neuren team has gained from the trofinetide Rett syndrome program across manufacturing, non-clinical, clinical and regulatory. Neuren is prioritising three indications in which NNZ-2591 can potentially have the maximum commercial value and the largest impact for patients. hareholders is enabled by financial strength 5 Phelan-McDermid syndrome Pitt Hopkins syndrome Hypoxic Ischemic Encephalopathy (HIE) NNZ-2591 (ercanetide) indications prioritised for maximum commercial impact rowth E® AYBUE 3 Angelman syndrome, Prader-Willi Syndrome, SYNGAP1, Rett syndrome (Acadia)*, Fragile X syndrome (Acadia)* NNZ-2591 (ercanetide) indications prioritised for maximum commercial impact Neuren Pharmaceuticals Limited Annual Report 2025 10
RkJQdWJsaXNoZXIy MjE2NDg3